BioNxt Solutions Inc. (CSE:BNXT)
0.5500
-0.0200 (-3.51%)
At close: Mar 20, 2026
BioNxt Solutions Revenue
BioNxt Solutions had revenue of 11.26K CAD in the quarter ending September 30, 2025, a decrease of -34.17%. This brings the company's revenue in the last twelve months to 15.82K, down -62.34% year-over-year. In the year 2024, BioNxt Solutions had annual revenue of 26.99K, down -92.75%.
Revenue (ttm)
15.82K
Revenue Growth
-62.34%
P/S Ratio
4,503.18
Revenue / Employee
n/a
Employees
20
Market Cap
71.25M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 26.99K | -345.26K | -92.75% |
| Dec 31, 2023 | 372.25K | 74.81K | 25.15% |
| Dec 31, 2022 | 297.44K | 10.94K | 3.82% |
| Dec 31, 2021 | 286.50K | -59.16K | -17.11% |
| Dec 31, 2020 | 345.65K | 137.54K | 66.08% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ascend Wellness Holdings | 686.36M |
| Planet 13 Holdings | 151.05M |
| Medexus Pharmaceuticals | 136.34M |
| Decibel Cannabis Company | 109.31M |
| HLS Therapeutics | 76.10M |
| Vext Science | 66.63M |
| C21 Investments | 45.62M |
| Leef Brands | 45.21M |
BioNxt Solutions News
- 5 days ago - BioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and Europe - Accesswire
- 23 days ago - BioNxt Announces Closing of Shares for Debt Settlement - Accesswire
- 4 weeks ago - BioNxt Receives Milestone EPO Decision to Grant European Patent for Sublingual Cladribine Drug Delivery Technology for Multiple Sclerosis - Accesswire
- 6 weeks ago - BioNxt Secures Innovative Chaperone Technology to Enhance Oral Thin-Film Drug Delivery - Accesswire
- 7 weeks ago - BioNxt Accelerates ODF for Multiple Sclerosis Toward Human Clinical Study with >40% Bioavailability Improvement and Myasthenia Gravis Expansion - Accesswire
- 2 months ago - BioNxt Reports Final Preclinical Results Demonstrating Approximately 40% Higher Cladribine Delivery for the Treatment Multiple Sclerosis (MS) - Accesswire
- 2 months ago - BioNxt Reports Successful Final In-Vivo Dosing Study Results Supporting Superior Bioavailability of Cladribine Sublingual ODF - Accesswire
- 3 months ago - Over 40% of Adults Struggle to Swallow Pills - BioNxt Targets a Global Adherence Problem with Rapid-Dissolving Thin-Film “Melt-in-Your-Mouth” Therapies - Accesswire